Eptifibatide: The evidence for its role in the management of acute coronary syndromes [Corrigendum]

Abstract

Shah I, Khan SO, Malhotra S, Fischell T. Core Evidence. 2009;4:49–65. Note that on pages 56 and 57, in the legends of both Table 3 and Table 4, the definition of TIMI is incorrectly stated as “TIMI, thrombosis in MI”. The correct legend should state “TIMI, thrombolysis in myocardial infarction”. On page 61, in line 6 of the first paragraph, note that “unadjusted heart rate” is incorrect, and should be “unadjusted hazard ratio”. On page 62, the last sentence is incorrectly provided as follows: “Given that the combination of abciximab plus reduced-dose fibrinolytic was associated with a significantly higher incidence of major and minor bleeding than treatment with a fibrinolytic [GUSTO-V76 and ASSENT-3,77 studies that are sufficiently powered for tolerability endpoints are required before firm conclusions can be drawn regarding the effect of a combination of eptifibatide and reduced-dose fibrinolytic on the incidence of major hemorrhage”. The correct sentence is: “Given that the combination of abciximab plus a reduced dose of fibrinolytic was associated with a significantly higher incidence of major and minor bleeding than treatment with a fibrinolytic agent alone [GUSTO-V76 and ASSENT-377] studies that are sufficiently powered for tolerability endpoints are required before firm conclusions can be drawn regarding the effect of a combination of eptifibatide and reduced-dose fibrinolytic”.